ROCKVILLE, Md.--(BUSINESS WIRE)-- Neogenix Oncology is pleased to announce that it will be granted a European Patent (“EP”) relating to its NEO-301 antibody (also known as 31.1), to take effect beginning September 23, 2011. The European Patent Office issued a “Decision to Grant” the company’s patent application, designated as EP Patent No. 02726672.5, on December 23, 2010. This patent will be in force until March 15, 2022.
NEO-301 specifically binds a variant of the A33 tumor antigen which is a target expressed on the majority of colorectal cancers, and was also found to be expressed by other cancers such as pancreatic cancer.
The allowed claims in the EP application broadly cover NEO-301 in naked and labeled form for use in treating pancreatic cancer as well as medicaments containing this antibody for treating pancreatic cancer. In addition, the allowed claims broadly cover the use of NEO-301 for diagnosis of pancreatic cancer and in diagnostic kits for detecting pancreatic cancer. This allowance expands the company’s patent protection relating to NEO-301 which includes US Patent No. 5,688,657 (reissued as RE39, 760) and numerous other pending patent applications.
This allowance further solidifies the company’s strategic focus and commitment to obtaining regulatory approval and patenting novel and improved immunologics for the treatment and detection of colorectal and pancreatic cancers. In a prior related announcement on November 1, 2010, the Company announced that they had received Orphan Drug status from the FDA for another of its proprietary antibodies, Ensituximab (NPC-1C or NEO-101), for use in the treatment of pancreatic cancer.
About Neogenix Oncology
Neogenix Oncology is a clinical stage biotechnology company focused on developing and commercializing therapeutic and diagnostic products for the early detection and treatment of pancreatic, colorectal, lung, cervical, ovarian, prostate, and other cancers. The company’s portfolio includes monoclonal antibodies that are designed to be specific to cancer cells by recognizing epitopes that are tumor specific, that is, found on cancer cells, but not normal cells. Founded in late 2003 and headquartered in Great Neck, NY, the company conducts its research and development work in its laboratories in Rockville, MD. The company is presently conducting a clinical study to establish certain of its antibodies as a serum diagnostic for pancreatic and colorectal cancers, and in December 2009 began a multicenter Phase I therapeutic trial to evaluate the clinical safety of the NPC-1C antibody in patients with metastatic pancreatic and colorectal cancer. For more information, visit www.neogenix.com.
Forward Looking Statements
Certain statements contained in this release are forward-looking statements that relate to future events. These statements are based on current expectations only and are subject to known and unknown risks, uncertainties and other factors which may cause the actual results to be materially different from any future results express or implied by such forward-looking statements, including those risk factors discussed in the company’s SEC reports, including the company’s annual report on Form 10-K and quarterly reports on Form 10-Q. These risks and uncertainties include, but are not limited to, risks associated with the company’s ability to successfully complete its product development efforts and obtain required regulatory approvals, obtain additional funding, develop commercially feasible products and services, successfully complete adequate and well-controlled clinical trials and generate revenues. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
RMT PR Management
RoseMarie Terenzio, 212-414-1909
KEYWORDS: United States Europe North America Maryland
INDUSTRY KEYWORDS: Health Biotechnology Clinical Trials Oncology